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Table 1: levels of quality assigned by the GRADE approach to assessing the confidence that can be 
assigned to the pooled effect estimate from a pairwise meta-analysis. “Current definition” adopted 
in 2011 series of articles published in Journal of Clinical Epidemiology. “Previous definition” used in 
2008 BMJ series of GRADE articles (see reference 5-7 for further information). 
 
 
Quality 
level 
Current definition Previous definition 
High 
We are very confident that the true effect lies close to 
that of the estimate of the effect 
Further research is very unlikely to change 
our confidence in the estimate of effect 
Moderate 
We are moderately confident in the effect estimate: 
The true effect is likely to be close to the estimate of 
the effect, but there is a possibility that it is 
substantially different 
Further research is likely to have an 
important impact on our confidence in the 
estimate of effect and may change the 
estimate 
Low 
Our confidence in the effect estimate is limited: The 
true effect may be substantially different from the 
estimate of the effect 
Further research is very likely to have an 
important impact on our confidence in the 
estimate of effect and is likely to change the 
estimate 
Very low 
We have very little confidence in the effect estimate: 
The true effect is likely to be substantially different from 
the estimate of effect 
Any estimate of effect is very uncertain 
Table 2a weight loss programs: Summary results (difference in mean weight loss (kg)) and GRADE assessment of the direct, indirect and NMA analyses. 
Adapted from [14]. Direct estimates were reported by original authors as being based on Der Simonian and Laird [37]; Network estimates were reported as 
based on hierarchical Bayesian network meta-regression [38] “accounting for exercise and behavioural support”[14].  
 
 
Comparison (active vs control) 
Mean difference (95% CI) Quality of Evidence (GRADE) 
Direct Indirect Network Direct Indirect Network 
LEARN vs No diet  
3.67  
(-3.88, 11.21) 
3.63  
(0.36, 6.91) 
5.16  
(2.68, 7.63) 
Low Low Low 
Moderate vs No diet 
4.84  
(2.82, 6.86) 
4.69 
 (1.73, 7.75) 
5.70 
 (4.14, 7.35) 
Low Low Moderate 
Low Carb vs No Diet 
9.34  
(7.31, 11.37) 
5.16  
(2.25, 8.18) 
7.25  
(5.33, 9.25) 
Low Moderate Moderate 
Low fat vs No diet 
5.97  
(2.01, 9.92) 
6.15  
(2.96, 9.40) 
7.27  
(5.26, 9.34) 
Moderate Moderate Moderate 
Moderate vs LEARN 
0.21  
(-4.64, 5.05) 
0.94  
(-1.74, 3.66) 
0.55 
 (-1.71, 2.87) 
Low Low Low 
Low Carb vs LEARN  
1.23  
(-1.22, 3.67)  
2.48  
-0.19, 5.19) 
2.10 
 (-0.20, 4.47) 
Low Low Low 
Low fat vs LEARN  
4.00  
(-0.21, 8.21)  
2.64  
(-0.02, 5.33) 
2.12 
 (-0.33, 4.59) 
Low Low Low 
Low Carb vs Moderate 
1.07 
 (0.16, 1.97) 
2.05  
(-0.92, 4.96) 
1.55 
 (0.13, 2.95) 
Moderate Low Moderate 
Low fat vs Moderate 
1.84 
 (0.96, 2.72) 
1.38 
 (-0.75, 3.51) 
1.56 
 (-0.17, 3.30) 
Moderate Low Moderate 
Low fat vs Low CHO 
0.33  
(-0.86, 1.52) 
0.39  
(-1.92, 2.70) 
0.02 
 (-1.78, 1.79) 
Low Moderate Moderate 
 
 
 
 
 
Table 2b Osteoporotic hip fractures GRADE NMA assessment of the direct, indirect and NMA analyses. Estimates are odds ratios (OR), where OR<1 favours 
active treatment. Adapted from [8]. Only comparisons for which direct data was available are shown here. Original authors report direct estimates as based 
on random effects models estimated by Comprehensive Meta-analysis version 2 [39]. Network estimates were reported [15] as being based on Bayesian 
random effects NMA using methods of Lu and Ades [3]  
 
 
 
Comparison (active vs control) 
Odds ratio (95% CI) Quality of Evidence (GRADE) 
Direct Indirect Network Direct Indirect Network 
Raloxifene v placebo 0.84 (0.63 to 1.13) 0.96 (0.53 to 1.78) 0.87 (0.63 to 1.22) Moderate Low Moderate 
Risedronate v placebo 0.17 (0.05 to 0.59) 0.54 (0.36 to 0.75) 0.48 (0.31 to 0.66) Low Low Low 
Vitamin D v placebo 1.25 (0.82 to 1.89) 1.08 (0.61; 1.91) 1.13 (0.94 to 1.34) Low Low Low 
Vitamin D+calcium v placebo 0.83 (0.73 to 0.96) 0.54 (0.29 to 0.94) 0.81 (0.68 to 0.96) Moderate Low Moderate 
Vit D+calcium v teriparatide 2.00 (0.50 to 8.33) - 1.92 (0.45 to 8.42) Low -  Low 
VitD+calcium v denosumab 1.67 (1.02 to 2.70) - 1.64 (0.97 to 2.87) Moderate -  Moderate 
Alendronate v raloxifene 0.49 (0.04 to 5.45) 0.53 (0.30 to 0.90) 0.51 (0.29 to 0.87) Low Moderate Moderate 
Vit D+calcium v raloxifene 0.88 (0.51 to 1.54) 0.96 (0.63 to 1.49) 0.94 (0.66 to 1.31) Moderate Low Moderate 
ViitD+calcium v zoledronate 1.64 (1.16 to 2.17) - 1.63 (1.16 to 2.30) High - High 
Vit D+calcium v risedronate 1.92 (0.84 to 4.35) 5.88 (1.79 to 25.00) 1.69 (1.27 to 2.54) Very low Low Low 
VitD+calcium v ibandronate 1.72 (0.76 to 3.85) - 1.69 (0.69 to 3.84) Low - Low 
Vitamin D v alendronate 3.70 (1.20 to 11.11) 2.38 (1.49 to 3.85) 2.54 (1.63 to 4.16) Moderate Moderate Moderate 
Vit D+calcium v alendronate 1.59 (1.03 to 2.44) 2.78 (1.14 to 8.33) 1.82 (1.24 to 2.90) Moderate Moderate Moderate 
Calcium v alendronate 4.55 (0.47 to 50.00) 2.56 (1.54 to 4.35) 2.56 (1.57 to 4.34) Very low Moderate Moderate 
VitD+calcium v vitamin D 1.03 (0.68 to 1.54) 0.65 (0.48 to 0.85) 0.72 (0.57 to 0.91) Low Low Low 
Calcium v calcium+vit D 1.21 (0.89 to 1.66) 3.43 (0.26 to 160.4) 1.40 (1.03 to 1.95) Low Very low Moderate 
Table 3. Base-case NMA based on the two-stage method, posterior summaries. The highlighted 
treatment, which would be recommended on the base-case analysis, is the one with the highest 
ranked mean treatment effect 
 
(a) Branded weight loss programs  
 
Treatment Pr(Best) Mean kg 
difference 
SD 
No diet 0 (reference) - 
LEARN 0.01 5.56 1.16 
Moderate 0 6.09 0.72 
Low Carb 0.17 7.49 0.72 
Low Fat 0.82 7.88 0.76 
 
 
(b) Hip fracture treatments in osteoporosis 
 
 Treatment Pr(Best) Log odds ratio SD 
Placebo 0.00 (reference) - 
Teriparatide 0.32 -0.87 0.72 
Denosumab 0.04 -0.69 0.26 
Raloxifene 0.00 -0.15 0.13 
Zoledronate 0.02 -0.68 0.17 
Risedronate 0.45 -1.12 0.35 
Ibandronate 0.12 -0.72 0.42 
Alendronate 0.05 -0.75 0.21 
VitD 0.00 0.04 0.15 
VitD+Calcium 0.00 -0.18 0.07 
Calcium 0.00 0.02 0.17 
Table 4a: Threshold analysis for branded weight loss programs [14] new recommended treatment (original was Low Fat), threshold at which new 
recommendation is made, and posterior residual mean deviance of the adjusted data NMA model at the threshold adjustment. The GRADE NMA 
assessment is from the last column in Table 2a. n.c. indicates No Change. n.f. (not found) indicates no threshold was found within + or – 5 kg.  
 
Entries in bold indicate evidence sources in which a plausible bias could change the treatment decision from Low Fat. For example, if the pair-wise evidence 
Low Carb vs Moderate was subject to a bias of -1kg or more, (ie the unbiased estimate was not the observed 1.07 kg, but 2.07 kg or higher), the treatment 
recommendation would change to Low Carb. 
 
 
Treatment B 
(active) 
Treatment A 
(control) 
Estimate  
(B relative to A) 
S.E. Trials Recommendation Bias 
Threshold, kg 
Deviance  GRADE 
NMA 
Learn No diet 3.67 3.85 2 n.c n.f - Low 
Moderate No diet 4.84 1.03 7 n.c n.f - Moderate 
Low carb No diet 9.34 1.04 1 n.c n.f - Moderate 
Low fat No diet 5.97 2.02 3 n.c n.f - Moderate 
Moderate Learn 0.21 2.47 2 n.c n.f - Low 
Low carb Learn 1.23 1.25 2 Learn 4.5 20.4 Low 
Low fat Learn 4.00 2.15 2 n.c n.f - Low 
Low carb Moderate 1.07 0.46 10 Low Carb -1.0 9.9 Moderate 
Low fat Moderate 1.84 0.45 4 Low Carb +0.9 12.1 Moderate 
Low fat Low carb 0.33 0.61 4 Low Carb +0.9 13.0 Moderate 
 
 
 
 
 
 
 
Table 4b. Threshold analysis drug treatments to prevent osteoporotic hip fractures [8, 15] Original treatment decision based on two-stage analysis was 
risedronate. For each data input we report the new recommended treatment, the threshold at which new recommendation is made and posterior residual 
mean deviance of the adjusted data NMA model at the threshold adjustment. The GRADE NMA assessment is from the last column in Table 2b.  n.c. 
indicates no change in recommended treatment. n.f. (not found) indicates no threshold was found within + or – 5 on a log odds ratio scale.  
 
For example; consider the pairwise (direct) evidence on placebo vs risedronate, if the pair-wise evidence was subject to a bias of +0.9 on the log odds ratio 
(LOR) scale or more, (ie the unbiased estimate was not the observed -1.77, but was -0.87 or higher), the treatment recommendation would change to 
Teriparatide.  
 
Treatment B 
(active) 
Treatment A 
(control) 
LOR S.E. 
 
Trials 
 
Recommendation 
 
Bias Threshold 
(LOR) 
Deviance 
 
GRADE 
NMA 
 
(B relative to A) 
Raloxifene  Placebo -0.17 0.24 1 Raloxifene -1.5 41.0 Moderate 
Risedronate Placebo -1.77 0.24 2 Teriparatide +0.9 13.8 Low 
Vit D  Placebo 0.22 0.69 9 Vit D -3 92.1 Low 
VitD+Calcium Placebo -0.19 0.04 8 Teriparatide -1 39.0 Moderate 
VitD+Calcium Teriparatide 0.69 2.30 1 Teriparatide +0.3 15.3 Low 
VitD+Calcium Denosumab  0.51 0.99 1 Denosumab +0.5 15.3 Moderate 
Alendronate Raloxifene  -0.71 2.52 1 n.c n.f - Moderate 
VitD+Calcium Raloxifene  -0.13 0.60 2 Raloxifene +4.5 196.0 Moderate 
VitD+Calcium Zoledronate 0.49 0.74 2 Zoledronate +0.5 15.3 High 
VitD+Calcium Risedronate  0.65 1.51 3 Teriperatide -0.4 16.9 Low 
VitD+Calcium Ibandronate  0.54 1.42 1 Ibandronate +0.4 15.3 Low 
VitD Alendronate  1.31 2.36 1 Alendronate +3.5 58.0 Moderate  
VitD+Calcium Alendronate  0.46 0.88 7 Alendronate +0.5 14.0 Moderate 
Calcium  Alendronate  1.52 4.10 1 n.c n.f - Moderate 
VitD+Calcium  VitD 0.03 0.53 2 VitD +2.5 115.2 Low 
Calcium  VitD+Calcium  0.19 0.54 4 Calcium -1.5 18.5 Moderate 
 
Table 5.  Relationship between distribution of GRADE NMA quality assessments, and the contrasts to 
which recommendations are sensitive 
 
 High Moderate Low Very Low Total 
Weight-loss 
   All contrasts 0 6 4 0 10 
   Sensitive contrasts 0 3 0 0 3 
Osteoporosis 
   All contrasts 1 9 6 0 16 
   Sensitive contrasts 1 2 4 0 7 
Figure 1a. Network of comparisons as described by Johnston [14]. Edge thickness is proportional to the 
number of trials contributing to that pair-wise contrast. Treatment nodes are not weighted. 
 
 
  
Figure 1b: Osteoporosis network adapted from [8] Edge thickness is proportional to the number of trials 
contributing to that pair-wise contrast. Treatment nodes proportional to number of participants. 
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